Identification

Name
Macimorelin
Accession Number
DB13074  (DB06066, DB05917)
Type
Small Molecule
Groups
Approved, Investigational
Description

Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels [3]. Growth hormone secretagogues (GHS) represent a new class of pharmacological agents which have the potential to be used in numerous clinical applications. They include treatment for growth retardation in children and cachexia associated with chronic disease such as AIDS and cancer.

Growth hormone (GH) is classically linked with linear growth during childhood. In deficiency of this hormone, AGHD is commonly associated with increased fat mass (particularly in the abdominal region), decreased lean body mass, osteopenia, dyslipidemia, insulin resistance, and/or glucose intolerance overtime. In addition, individuals with may be susceptible to cardiovascular complications from altered structures and function [5]. Risk factors of AGHD include a history of childhood-onset GH deficiency or with hypothalamic/pituitary disease, surgery, or irradiation to these areas, head trauma, or evidence of other pituitary hormone deficiencies [3]. While there are various therapies available such as GH replacement therapy, the absence of panhypopituitarism and low serum IGF-I levels with nonspecific clinical symptoms pose challenges to the detection and diagnosis of AGHD. The diagnosis of AGHD requires biochemical confirmation with at least 1 GH stimulation test [3]. Macimorelin is clinically useful since it displays good stability and oral bioavailability with comparable affinity to ghrelin receptor as its endogenous ligand. In clinical studies involving healthy subjects, macimorelin stimulated GH release in a dose-dependent manner with good tolerability [3].

Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution.

Structure
Thumb
Synonyms
Not Available
External IDs
ARD 07 / ARD-07 / D-87575 / EP 1572 / EP-01572 / EP-1572 / JMV-1843
Product Ingredients
IngredientUNIICASInChI Key
Macimorelin acetateAQZ1003RMG945212-59-9WVDSKQXKCDZXLH-OHIDFYLOSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MacrilenGranule, for solution60 mg/mgOralStrongbridge U.S. Inc2018-01-29Not applicableUs
Categories
UNII
8680B21W73
CAS number
381231-18-1
Weight
Average: 474.565
Monoisotopic: 474.23793885
Chemical Formula
C26H30N6O3
InChI Key
UJVDJAPJQWZRFR-DHIUTWEWSA-N
InChI
InChI=1S/C26H30N6O3/c1-26(2,27)25(35)31-22(11-16-13-28-20-9-5-3-7-18(16)20)24(34)32-23(30-15-33)12-17-14-29-21-10-6-4-8-19(17)21/h3-10,13-15,22-23,28-29H,11-12,27H2,1-2H3,(H,30,33)(H,31,35)(H,32,34)/t22-,23-/m1/s1
IUPAC Name
(2R)-2-(2-amino-2-methylpropanamido)-3-(1H-indol-3-yl)-N-[(1R)-2-(1H-indol-3-yl)-1-formamidoethyl]propanamide
SMILES
CC(C)(N)C(=O)N[[email protected]](CC1=CNC2=CC=CC=C12)C(=O)N[[email protected]](CC1=CNC2=CC=CC=C12)NC=O

Pharmacology

Indication

Indicated for the diagnosis of adult growth hormone deficiency (AGHD) [FDA Label].

Structured Indications
Not Available
Pharmacodynamics

Maximum GH levels from stimulation are observed between 30 to 90 minutes after administration of macimorelin [FDA Label]. Increase in the QTcF interval may be observed from macimorelin administration [FDA Label].

Mechanism of action

Ghrelin is an endogenous ligand for the GH secretagogue receptor that is also called the ghrelin receptor (GHS-R1a). Upon activation of the receptor, ghrelin serves to increase growth hormone (GH) secretion. Macimorelin mimics the actions of ghrelin by stimulating GH release. As a synthetic agonist, it activates growth hormone secretagogue receptors present in the pituitary and hypothalamus.

TargetActionsOrganism
UGrowth hormone secretagogue receptor type 1
agonist
Human
Absorption

Macimorelin is a novel, synthetic ghrelin agonist, which is readily absorbed from the gastrointestinal tract [4]. The maximum plasma concentration (Cmax) was observed between 0.5 and 1.5 hours following oral administration of 0.5mg/kg macimorelin to patients with AGHD under fasting for at least 8 hours. Higher doses of drug demonstrate a dose-proportional increase in plasma concentrations [4]. A liquid meal decreased the macimorelin Cmax and AUC by 55% and 49%, respectively [FDA Label].

Volume of distribution

Following a single oral dose of 0.5 mg/kg macimorelin, the mean volume of distribution of the central compartment is 5,733.4 ± 565.7L [4].

Protein binding
Not Available
Metabolism

Macimorelin predominantly undergoes CYP3A4-mediated metabolism according to an in vitro human liver microsomes study [FDA Label].

Route of elimination
Not Available
Half life

The mean terminal half-life (T1/2) is 4.1 hours following administration of a single oral dose of 0.5 mg macimorelin/kg body weight in healthy subjects [FDA Label].

Clearance

Following a single oral dose of 0.5 mg/kg macimorelin, the mean clearance over the fraction absorbed (Cl/F) was 37,411.0 ± 4,554.6 mL/min [4].

Toxicity

Macimorelin has not shown to demonstrate mutagenic properties according to bacterial assays. It also did not induce any mutations or clastogenic effects in mouse lymphoma cells with or without metabolic activation. Studies assessing the carcinogenic potential or effect on fertility of macimorelin have not been conducted [FDA Label].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AmiodaroneAmiodarone may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
AnagrelideAnagrelide may increase the QTc-prolonging activities of Macimorelin.Approved
ApalutamideThe serum concentration of Macimorelin can be decreased when it is combined with Apalutamide.Approved, Investigational
AprepitantThe serum concentration of Macimorelin can be increased when it is combined with Aprepitant.Approved, Investigational
Arsenic trioxideArsenic trioxide may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
AstemizoleAstemizole may increase the QTc-prolonging activities of Macimorelin.Approved, Withdrawn
AtazanavirThe metabolism of Macimorelin can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Macimorelin can be decreased when combined with Atomoxetine.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Macimorelin.Approved
BepridilBepridil may increase the QTc-prolonging activities of Macimorelin.Approved, Withdrawn
BoceprevirThe metabolism of Macimorelin can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Macimorelin can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Macimorelin can be decreased when it is combined with Bosentan.Approved, Investigational
CarbamazepineThe serum concentration of Macimorelin can be decreased when it is combined with Carbamazepine.Approved, Investigational
CeritinibThe serum concentration of Macimorelin can be increased when it is combined with Ceritinib.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational, Vet Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational, Vet Approved
CilostazolCilostazol may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
CisaprideCisapride may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational, Withdrawn
CitalopramCitalopram may increase the QTc-prolonging activities of Macimorelin.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Macimorelin.Approved
ClemastineThe metabolism of Macimorelin can be decreased when combined with Clemastine.Approved, Investigational
ClotrimazoleThe metabolism of Macimorelin can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Macimorelin can be decreased when combined with Cobicistat.Approved
CocaineCocaine may increase the QTc-prolonging activities of Macimorelin.Approved, Illicit
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Macimorelin.Approved, Investigational
CrizotinibThe metabolism of Macimorelin can be decreased when combined with Crizotinib.Approved
CyclosporineThe metabolism of Macimorelin can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Macimorelin can be decreased when it is combined with Dabrafenib.Approved, Investigational
DarunavirThe metabolism of Macimorelin can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Macimorelin can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Macimorelin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Macimorelin can be decreased when combined with Delavirdine.Approved
DihydroergotamineThe metabolism of Macimorelin can be decreased when combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe metabolism of Macimorelin can be decreased when combined with Diltiazem.Approved, Investigational
DisopyramideDisopyramide may increase the QTc-prolonging activities of Macimorelin.Approved
DofetilideDofetilide may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
DomperidoneDomperidone may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational, Vet Approved
DonepezilDonepezil may increase the QTc-prolonging activities of Macimorelin.Approved
DoxycyclineThe metabolism of Macimorelin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneDronedarone may increase the QTc-prolonging activities of Macimorelin.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Macimorelin.Approved, Vet Approved
EnzalutamideThe serum concentration of Macimorelin can be decreased when it is combined with Enzalutamide.Approved
ErythromycinErythromycin may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational, Vet Approved
EscitalopramEscitalopram may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Macimorelin.Approved, Withdrawn
FluconazoleFluconazole may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
FluvoxamineThe metabolism of Macimorelin can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Macimorelin can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Macimorelin can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Macimorelin can be decreased when it is combined with Fosphenytoin.Approved, Investigational
Fusidic AcidThe serum concentration of Macimorelin can be increased when it is combined with Fusidic Acid.Approved, Investigational
GatifloxacinGatifloxacin may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
GrepafloxacinGrepafloxacin may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational, Withdrawn
HalofantrineHalofantrine may increase the QTc-prolonging activities of Macimorelin.Approved
HaloperidolHaloperidol may increase the QTc-prolonging activities of Macimorelin.Approved
IbutilideIbutilide may increase the QTc-prolonging activities of Macimorelin.Approved
IdelalisibThe metabolism of Macimorelin can be decreased when combined with Idelalisib.Approved
ImatinibThe metabolism of Macimorelin can be decreased when combined with Imatinib.Approved
IndinavirThe metabolism of Macimorelin can be decreased when combined with Indinavir.Approved
IsavuconazoleThe serum concentration of Macimorelin can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Macimorelin can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Macimorelin can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Macimorelin can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Macimorelin can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Macimorelin can be decreased when combined with Ketoconazole.Approved, Investigational
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
Levomethadyl AcetateLevomethadyl Acetate may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
LopinavirThe metabolism of Macimorelin can be decreased when combined with Lopinavir.Approved
LorpiprazoleThe serum concentration of Macimorelin can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe metabolism of Macimorelin can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Macimorelin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Macimorelin can be decreased when it is combined with Lumacaftor.Approved
MesoridazineMesoridazine may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
MethadoneMethadone may increase the QTc-prolonging activities of Macimorelin.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
MifepristoneThe serum concentration of Macimorelin can be increased when it is combined with Mifepristone.Approved, Investigational
MitotaneThe serum concentration of Macimorelin can be decreased when it is combined with Mitotane.Approved
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
NefazodoneThe metabolism of Macimorelin can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Macimorelin can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Macimorelin can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Macimorelin can be decreased when it is combined with Nevirapine.Approved
NilotinibThe metabolism of Macimorelin can be decreased when combined with Nilotinib.Approved, Investigational
OlaparibThe metabolism of Macimorelin can be decreased when combined with Olaparib.Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Macimorelin.Approved
OsimertinibThe serum concentration of Macimorelin can be increased when it is combined with Osimertinib.Approved
OxaliplatinOxaliplatin may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
PalbociclibThe serum concentration of Macimorelin can be increased when it is combined with Palbociclib.Approved, Investigational
PapaverinePapaverine may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
PentamidinePentamidine may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
PentobarbitalThe serum concentration of Macimorelin can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PhenobarbitalThe serum concentration of Macimorelin can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenytoinThe serum concentration of Macimorelin can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozidePimozide may increase the QTc-prolonging activities of Macimorelin.Approved
PitolisantThe serum concentration of Macimorelin can be decreased when it is combined with Pitolisant.Approved, Investigational
PosaconazoleThe metabolism of Macimorelin can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe serum concentration of Macimorelin can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbucolProbucol may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
ProcainamideProcainamide may increase the QTc-prolonging activities of Macimorelin.Approved
PropofolPropofol may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational, Vet Approved
QuinidineQuinidine may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
RanolazineThe metabolism of Macimorelin can be decreased when combined with Ranolazine.Approved, Investigational
RifabutinThe serum concentration of Macimorelin can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Macimorelin can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Macimorelin can be decreased when it is combined with Rifapentine.Approved, Investigational
RoxithromycinRoxithromycin may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational, Withdrawn
RucaparibThe metabolism of Macimorelin can be decreased when combined with Rucaparib.Approved, Investigational
SaquinavirThe metabolism of Macimorelin can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Macimorelin can be decreased when used in combination with Sarilumab.Approved, Investigational
SevofluraneSevoflurane may increase the QTc-prolonging activities of Macimorelin.Approved, Vet Approved
SildenafilThe metabolism of Macimorelin can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Macimorelin can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Macimorelin can be increased when it is combined with Simeprevir.Approved
SotalolSotalol may increase the QTc-prolonging activities of Macimorelin.Approved
SparfloxacinSparfloxacin may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
St. John's WortThe serum concentration of Macimorelin can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Macimorelin can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Macimorelin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideSulpiride may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
SultoprideSultopride may increase the QTc-prolonging activities of Macimorelin.Experimental
TelaprevirThe metabolism of Macimorelin can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Macimorelin can be decreased when combined with Telithromycin.Approved
TerfenadineTerfenadine may increase the QTc-prolonging activities of Macimorelin.Approved, Withdrawn
TerlipressinTerlipressin may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
TerodilineTerodiline may increase the QTc-prolonging activities of Macimorelin.Experimental
ThioridazineThioridazine may increase the QTc-prolonging activities of Macimorelin.Approved, Withdrawn
TiclopidineThe metabolism of Macimorelin can be decreased when combined with Ticlopidine.Approved
TocilizumabThe serum concentration of Macimorelin can be decreased when it is combined with Tocilizumab.Approved
VandetanibVandetanib may increase the QTc-prolonging activities of Macimorelin.Approved
VemurafenibThe serum concentration of Macimorelin can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Macimorelin can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Macimorelin can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Macimorelin can be decreased when combined with Voriconazole.Approved, Investigational
ZiprasidoneThe metabolism of Macimorelin can be decreased when combined with Ziprasidone.Approved
Food Interactions
Not Available

References

General References
  1. Guerlavais V, Boeglin D, Mousseaux D, Oiry C, Heitz A, Deghenghi R, Locatelli V, Torsello A, Ghe C, Catapano F, Muccioli G, Galleyrand JC, Fehrentz JA, Martinez J: New active series of growth hormone secretagogues. J Med Chem. 2003 Mar 27;46(7):1191-203. [PubMed:12646029]
  2. Broglio F, Boutignon F, Benso A, Gottero C, Prodam F, Arvat E, Ghe C, Catapano F, Torsello A, Locatelli V, Muccioli G, Boeglin D, Guerlavais V, Fehrentz JA, Martinez J, Ghigo E, Deghenghi R: EP1572: a novel peptido-mimetic GH secretagogue with potent and selective GH-releasing activity in man. J Endocrinol Invest. 2002 Sep;25(8):RC26-8. [PubMed:12240910]
  3. Garcia JM, Swerdloff R, Wang C, Kyle M, Kipnes M, Biller BM, Cook D, Yuen KC, Bonert V, Dobs A, Molitch ME, Merriam GR: Macimorelin (AEZS-130)-stimulated growth hormone (GH) test: validation of a novel oral stimulation test for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab. 2013 Jun;98(6):2422-9. doi: 10.1210/jc.2013-1157. Epub 2013 Apr 4. [PubMed:23559086]
  4. Piccoli F, Degen L, MacLean C, Peter S, Baselgia L, Larsen F, Beglinger C, Drewe J: Pharmacokinetics and pharmacodynamic effects of an oral ghrelin agonist in healthy subjects. J Clin Endocrinol Metab. 2007 May;92(5):1814-20. doi: 10.1210/jc.2006-2160. Epub 2007 Feb 6. [PubMed:17284637]
  5. Fukuda I, Hizuka N, Muraoka T, Ichihara A: Adult growth hormone deficiency: current concepts. Neurol Med Chir (Tokyo). 2014;54(8):599-605. Epub 2014 Jul 28. [PubMed:25070016]
External Links
KEGG Drug
D10563
ChemSpider
7980698
BindingDB
50125886
ChEMBL
CHEMBL278623
Wikipedia
Macimorelin
ATC Codes
V04CD06 — Macimorelin
FDA label
Download (280 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentCancer Cachexia1
3CompletedDiagnosticGrowth Hormone Deficiency With Pituitary Anomalies1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Granule, for solutionOral60 mg/mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8192719No2007-10-122027-10-12Us
US6861409No2002-08-012022-08-01Us

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00616 mg/mLALOGPS
logP1.77ALOGPS
logP1.67ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)12.4ChemAxon
pKa (Strongest Basic)8.34ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area144.9 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity133.14 m3·mol-1ChemAxon
Polarizability49.05 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
N-acyl-alpha amino acids and derivatives / Tryptamines and derivatives / Alpha amino acid amides / 3-alkylindoles / Substituted pyrroles / Fatty amides / Benzenoids / Heteroaromatic compounds / Secondary carboxylic acid amides / Azacyclic compounds
show 4 more
Substituents
Alpha-dipeptide / N-acyl-alpha amino acid or derivatives / Alpha-amino acid amide / Triptan / N-substituted-alpha-amino acid / Alpha-amino acid or derivatives / 3-alkylindole / Indole or derivatives / Indole / Fatty acyl
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Peptide hormone binding
Specific Function
Receptor for ghrelin, coupled to G-alpha-11 proteins. Stimulates growth hormone secretion. Binds also other growth hormone releasing peptides (GHRP) (e.g. Met-enkephalin and GHRP-6) as well as non-...
Gene Name
GHSR
Uniprot ID
Q92847
Uniprot Name
Growth hormone secretagogue receptor type 1
Molecular Weight
41328.045 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da

Drug created on October 20, 2016 20:42 / Updated on May 02, 2018 01:43